The disclosure provides a pharmaceutical composition for use in treating fibrosis comprising a reovirus as an active ingredient.

This document relates to methods and materials involved in treating cancer. For example, methods and materials for using one or more oncolytic viruses (OVs) in combination with an adoptive cell therapy (e.g., a chimeric antigen receptor T cell therapy) to alter one or more functions of a T cell and/or to enhance T cell expansion to treat cancer in a mammal (e.g., a human) are provided.

The present disclosure provides modified reovirus with improved characteristics, including improved oncolytic activity. Reoviruses provided herein include resortant viruses as well as viruses expressing mutated proteins. Methods of using such modified reovirus for inducing cancer cell lysis as well as treatment of cancer are disclosed. Also provided are methods tailored for induction of a desired cytokine profile in conjunction with, e.g., methods of inducing cancer cell oncolysis.

The present disclosure provides modified reovirus with improved characteristics, including improved oncolytic activity. Reoviruses provided herein include resortant viruses as well as viruses expressing mutated proteins. Methods of using such modified reovirus for inducing cancer cell lysis as well as treatment of cancer are disclosed. Also provided are methods tailored for induction of a desired cytokine profile in conjunction with, e.g., methods of inducing cancer cell oncolysis.

The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.

The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.

The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.

A versatile carrier system for systemic delivery of oncolytic viruses comprises dendritic cells having at least one oncolytic virus loaded therein. It is believed that the dendritic cells will protect the oncolytic virus(es) against neutralizing antibodies, can transport the oncolytic virus(es) to targeted tumor locations, and then deliver virions to the tumor locations.

The present disclosure relates to one or more modified avian-virus based agents, therapies, treatments, and methods of use of the modified avian-virus based agents and/or therapies and/or treatments for cancer. The disclosure also provides for methods of generating modified avian-virus based agents.

The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.